Ethotoin

Ethotoin

File:Ethotoin.png
Clinical data
Pregnancy category	C
Routes of administration	Oral
ATC code	N03AB01 (WHO)
Pharmacokinetic data
Elimination half-life	3 to 9 hours
Identifiers
IUPAC name 3-ethyl-5-phenyl-imidazolidine-2,4-dione
CAS Number	86-35-1
PubChem CID	3292
DrugBank	APRD00962
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H12N2O2
Molar mass	204.225 g/mol

Ethotoin (marketed as Peganone® by Ovation) is an anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. Ethotoin lacks phenytoin's side effects of gingival hyperplasia and hirsutism, however it is less effective. This, combined with the need for frequent dosing has limited its usefulness. Ethotoin is no longer widely used.

Mechanism of action

Similar to phenytoin.

Approval history

• 1957 Peganone was granted Food and Drug Administration (FDA) approval to Abbott Laboratories for treatment of grand mal (tonic clonic) and partial complex (psychomotor) seizures.
• 2003 Peganone was acquired from Abbott Laboratories by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).

Indications and usage

Ethotoin is indicated for tonic-clonic and partial complex seizures.

Dosing

Ethotoin is available in 250mg tablets. It is taken orally in 4 to 6 divided doses per day, preferably after food.

Side effects

Ataxia, visual disturbances, rash and gastrointestinal problems.

References

• Peganone, a new antiepileptic drug.

Dis Nerv Syst. 1956 May;17(5):155-8.

Schwade ED, Richards RK, Everett GM. PMID 13317788

• The Treatment of Epilepsy edited by S. D. Shorvon, David R. Fish, Emilio Perucca, W. Edwin Dodson. Blackwell Publishing. 2004. ISBN 0-632-06046-8
• Drugs.com: Ethotoin
• PEGANONE® 250 mg Ethotoin Tablets, USP (PDF)

External links

• Ovation Pharmaceuticals